Global Pulmonary Arterial Hypertension Treatment Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

  • receipt Report ID : 147469
  • calendar_today Published On: Apr, 2019
  • file_copy Pages: 135
  • list Pharmaceuticals and Healthcare

Pulmonary arterial hypertension- commonly known as PAH- is characterized by increased pressure in the pulmonary arteries due to structural changes in blood vessel walls, aggregation of platelets and alteration of smooth muscle cell function- eventually elevating pressure in the pulmonary arteries responsible for pumping blood to the lungs. This eventually leads to right heart failure and, ultimately, death.

Scope of the Report:

This report focuses on the Pulmonary Arterial Hypertension Treatment in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

The worldwide market for Pulmonary Arterial Hypertension Treatment is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.

Market Segment by Manufacturers, this report covers

GlaxoSmithKline plc

Eli Lilly and Company

Pfizer Inc.Actelion Inc

United Therapeutic Corporation

SteadyMed Ltd

Gilead Sciences, Inc

Teva Pharmaceuticals Inc

Bayer AG

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Vasodilators

Phosphodiesterase 5 (PDE 5) Inhibitors

Endothelin Receptor Antagonists (ERA)

Soluble Guanylate Cyclase (SGC) Stimulator

Market Segment by Applications, can be divided into

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

There are 15 Chapters to deeply display the global Pulmonary Arterial Hypertension Treatment market.

Chapter 1, to describe Pulmonary Arterial Hypertension Treatment Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Pulmonary Arterial Hypertension Treatment, with sales, revenue, and price of Pulmonary Arterial Hypertension Treatment, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Pulmonary Arterial Hypertension Treatment, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, Pulmonary Arterial Hypertension Treatment market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe Pulmonary Arterial Hypertension Treatment sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 Market Overview

1.1 Pulmonary Arterial Hypertension Treatment Introduction

1.2 Market Analysis by Type

1.2.1 Vasodilators

1.2.2 Phosphodiesterase 5 (PDE 5) Inhibitors

1.2.3 Endothelin Receptor Antagonists (ERA)

1.2.4 Soluble Guanylate Cyclase (SGC) Stimulator

1.3 Market Analysis by Applications

1.3.1 Hospital Pharmacies

1.3.2 Retail Pharmacies

1.3.3 Online Pharmacies

1.4 Market Analysis by Regions

1.4.1 North America (United States, Canada and Mexico)

1.4.1.1 United States Market States and Outlook (2013-2023)

1.4.1.2 Canada Market States and Outlook (2013-2023)

1.4.1.3 Mexico Market States and Outlook (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy)

1.4.2.1 Germany Market States and Outlook (2013-2023)

1.4.2.2 France Market States and Outlook (2013-2023)

1.4.2.3 UK Market States and Outlook (2013-2023)

1.4.2.4 Russia Market States and Outlook (2013-2023)

1.4.2.5 Italy Market States and Outlook (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

1.4.3.1 China Market States and Outlook (2013-2023)

1.4.3.2 Japan Market States and Outlook (2013-2023)

1.4.3.3 Korea Market States and Outlook (2013-2023)

1.4.3.4 India Market States and Outlook (2013-2023)

1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)

1.4.4 South America, Middle East and Africa

1.4.4.1 Brazil Market States and Outlook (2013-2023)

1.4.4.2 Egypt Market States and Outlook (2013-2023)

1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)

1.4.4.4 South Africa Market States and Outlook (2013-2023)

1.4.4.5 Nigeria Market States and Outlook (2013-2023)

1.5 Market Dynamics

1.5.1 Market Opportunities

1.5.2 Market Risk

1.5.3 Market Driving Force

2 Manufacturers Profiles

2.1 GlaxoSmithKline plc

2.1.1 Business Overview

2.1.2 Pulmonary Arterial Hypertension Treatment Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 GlaxoSmithKline plc Pulmonary Arterial Hypertension Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.2 Eli Lilly and Company

2.2.1 Business Overview

2.2.2 Pulmonary Arterial Hypertension Treatment Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.3 Pfizer Inc.Actelion Inc

2.3.1 Business Overview

2.3.2 Pulmonary Arterial Hypertension Treatment Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Pfizer Inc.Actelion Inc Pulmonary Arterial Hypertension Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.4 United Therapeutic Corporation

2.4.1 Business Overview

2.4.2 Pulmonary Arterial Hypertension Treatment Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.5 SteadyMed Ltd

2.5.1 Business Overview

2.5.2 Pulmonary Arterial Hypertension Treatment Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.6 Gilead Sciences, Inc

2.6.1 Business Overview

2.6.2 Pulmonary Arterial Hypertension Treatment Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.7 Teva Pharmaceuticals Inc

2.7.1 Business Overview

2.7.2 Pulmonary Arterial Hypertension Treatment Type and Applications

2.7.2.1 Product A

2.7.2.2 Product B

2.7.3 Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.8 Bayer AG

2.8.1 Business Overview

2.8.2 Pulmonary Arterial Hypertension Treatment Type and Applications

2.8.2.1 Product A

2.8.2.2 Product B

2.8.3 Bayer AG Pulmonary Arterial Hypertension Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

3 Global Pulmonary Arterial Hypertension Treatment Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)

3.1 Global Pulmonary Arterial Hypertension Treatment Sales and Market Share by Manufacturer (2016-2017)

3.2 Global Pulmonary Arterial Hypertension Treatment Revenue and Market Share by Manufacturer (2016-2017)

3.3 Market Concentration Rate

3.3.1 Top 3 Pulmonary Arterial Hypertension Treatment Manufacturer Market Share in 2017

3.3.2 Top 6 Pulmonary Arterial Hypertension Treatment Manufacturer Market Share in 2017

3.4 Market Competition Trend

4 Global Pulmonary Arterial Hypertension Treatment Market Analysis by Regions

4.1 Global Pulmonary Arterial Hypertension Treatment Sales, Revenue and Market Share by Regions

4.1.1 Global Pulmonary Arterial Hypertension Treatment Sales and Market Share by Regions (2013-2018)

4.1.2 Global Pulmonary Arterial Hypertension Treatment Revenue and Market Share by Regions (2013-2018)

4.2 North America Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2013-2018)

4.3 Europe Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2013-2018)

4.4 Asia-Pacific Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2013-2018)

4.5 South America Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2013-2018)

4.6 Middle East and Africa Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2013-2018)

5 North America Pulmonary Arterial Hypertension Treatment by Countries

5.1 North America Pulmonary Arterial Hypertension Treatment Sales, Revenue and Market Share by Countries

5.1.1 North America Pulmonary Arterial Hypertension Treatment Sales and Market Share by Countries (2013-2018)

5.1.2 North America Pulmonary Arterial Hypertension Treatment Revenue and Market Share by Countries (2013-2018)

5.2 United States Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2013-2018)

5.3 Canada Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2013-2018)

5.4 Mexico Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2013-2018)

6 Europe Pulmonary Arterial Hypertension Treatment by Countries

6.1 Europe Pulmonary Arterial Hypertension Treatment Sales, Revenue and Market Share by Countries

6.1.1 Europe Pulmonary Arterial Hypertension Treatment Sales and Market Share by Countries (2013-2018)

6.1.2 Europe Pulmonary Arterial Hypertension Treatment Revenue and Market Share by Countries (2013-2018)

6.2 Germany Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2013-2018)

6.3 UK Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2013-2018)

6.4 France Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2013-2018)

6.5 Russia Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2013-2018)

6.6 Italy Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2013-2018)

7 Asia-Pacific Pulmonary Arterial Hypertension Treatment by Countries

7.1 Asia-Pacific Pulmonary Arterial Hypertension Treatment Sales, Revenue and Market Share by Countries

7.1.1 Asia-Pacific Pulmonary Arterial Hypertension Treatment Sales and Market Share by Countries (2013-2018)

7.1.2 Asia-Pacific Pulmonary Arterial Hypertension Treatment Revenue and Market Share by Countries (2013-2018)

7.2 China Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2013-2018)

7.3 Japan Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2013-2018)

7.4 Korea Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2013-2018)

7.5 India Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2013-2018)

7.6 Southeast Asia Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2013-2018)

8 South America Pulmonary Arterial Hypertension Treatment by Countries

8.1 South America Pulmonary Arterial Hypertension Treatment Sales, Revenue and Market Share by Countries

8.1.1 South America Pulmonary Arterial Hypertension Treatment Sales and Market Share by Countries (2013-2018)

8.1.2 South America Pulmonary Arterial Hypertension Treatment Revenue and Market Share by Countries (2013-2018)

8.2 Brazil Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2013-2018)

8.3 Argentina Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2013-2018)

8.4 Colombia Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2013-2018)

9 Middle East and Africa Pulmonary Arterial Hypertension Treatment by Countries

9.1 Middle East and Africa Pulmonary Arterial Hypertension Treatment Sales, Revenue and Market Share by Countries

9.1.1 Middle East and Africa Pulmonary Arterial Hypertension Treatment Sales and Market Share by Countries (2013-2018)

9.1.2 Middle East and Africa Pulmonary Arterial Hypertension Treatment Revenue and Market Share by Countries (2013-2018)

9.2 Saudi Arabia Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2013-2018)

9.3 UAE Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2013-2018)

9.4 Egypt Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2013-2018)

9.5 Nigeria Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2013-2018)

9.6 South Africa Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2013-2018)

10 Global Pulmonary Arterial Hypertension Treatment Market Segment by Type

10.1 Global Pulmonary Arterial Hypertension Treatment Sales, Revenue and Market Share by Type (2013-2018)

10.1.1 Global Pulmonary Arterial Hypertension Treatment Sales and Market Share by Type (2013-2018)

10.1.2 Global Pulmonary Arterial Hypertension Treatment Revenue and Market Share by Type (2013-2018)

10.2 Vasodilators Sales Growth and Price

10.2.1 Global Vasodilators Sales Growth (2013-2018)

10.2.2 Global Vasodilators Price (2013-2018)

10.3 Phosphodiesterase 5 (PDE 5) Inhibitors Sales Growth and Price

10.3.1 Global Phosphodiesterase 5 (PDE 5) Inhibitors Sales Growth (2013-2018)

10.3.2 Global Phosphodiesterase 5 (PDE 5) Inhibitors Price (2013-2018)

10.4 Endothelin Receptor Antagonists (ERA) Sales Growth and Price

10.4.1 Global Endothelin Receptor Antagonists (ERA) Sales Growth (2013-2018)

10.4.2 Global Endothelin Receptor Antagonists (ERA) Price (2013-2018)

10.5 Soluble Guanylate Cyclase (SGC) Stimulator Sales Growth and Price

10.5.1 Global Soluble Guanylate Cyclase (SGC) Stimulator Sales Growth (2013-2018)

10.5.2 Global Soluble Guanylate Cyclase (SGC) Stimulator Price (2013-2018)

11 Global Pulmonary Arterial Hypertension Treatment Market Segment by Application

11.1 Global Pulmonary Arterial Hypertension Treatment Sales Market Share by Application (2013-2018)

11.2 Hospital Pharmacies Sales Growth (2013-2018)

11.3 Retail Pharmacies Sales Growth (2013-2018)

11.4 Online Pharmacies Sales Growth (2013-2018)

12 Pulmonary Arterial Hypertension Treatment Market Forecast (2018-2023)

12.1 Global Pulmonary Arterial Hypertension Treatment Sales, Revenue and Growth Rate (2018-2023)

12.2 Pulmonary Arterial Hypertension Treatment Market Forecast by Regions (2018-2023)

12.2.1 North America Pulmonary Arterial Hypertension Treatment Market Forecast (2018-2023)

12.2.2 Europe Pulmonary Arterial Hypertension Treatment Market Forecast (2018-2023)

12.2.3 Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Forecast (2018-2023)

12.2.4 South America Pulmonary Arterial Hypertension Treatment Market Forecast (2018-2023)

12.2.5 Middle East and Africa Pulmonary Arterial Hypertension Treatment Market Forecast (2018-2023)

12.3 Pulmonary Arterial Hypertension Treatment Market Forecast by Type (2018-2023)

12.3.1 Global Pulmonary Arterial Hypertension Treatment Sales Forecast by Type (2018-2023)

12.3.2 Global Pulmonary Arterial Hypertension Treatment Market Share Forecast by Type (2018-2023)

12.4 Pulmonary Arterial Hypertension Treatment Market Forecast by Application (2018-2023)

12.4.1 Global Pulmonary Arterial Hypertension Treatment Sales Forecast by Application (2018-2023)

12.4.2 Global Pulmonary Arterial Hypertension Treatment Market Share Forecast by Application (2018-2023)

13 Sales Channel, Distributors, Traders and Dealers

13.1 Sales Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.1.3 Marketing Channel Future Trend

13.2 Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

15.1 Methodology

15.2 Data Source

List of Tables and Figures

Figure Pulmonary Arterial Hypertension Treatment Picture

Table Product Specifications of Pulmonary Arterial Hypertension Treatment

Figure Global Sales Market Share of Pulmo

Please fill the form below, to recieve the report sample


+1

Choose License Type

Reach Us

Email us at

sales@mrinsights.biz

Or call us on

US +1-201-465-4211

IND +91-906-779-0957

Why Choose Us

ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems

Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system

Global Outreach6 Major regions and 40+ countries level analysis accomplished

Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery